State Street Corp Harpoon Therapeutics, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.94 - $2.56 $4,418 - $12,032	-4,700 Reduced 5.23%	85,232 $83,000
Q2 2022 Aug 15, 2022	SELL	$1.78 - $5.02 $628,939 - $1.77 Million	-353,337 Reduced 79.71%	89,932 $172,000
Q1 2022 May 16, 2022	BUY	$3.54 - $8.08 $208,544 - $476,000	58,911 Added 15.33%	443,269 $2.2 Million
Q4 2021 Feb 14, 2022	BUY	$5.69 - $7.83 $3,607 - $4,964	634 Added 0.17%	384,358 $2.9 Million
Q3 2021 Nov 15, 2021	SELL	$7.88 - $14.0 $7.44 Million - $13.2 Million	-944,644 Reduced 71.11%	383,724 $3.03 Million
Q2 2021 Aug 16, 2021	BUY	$13.81 - $23.25 $15.5 Million - $26.1 Million	1,123,701 Added 549.04%	1,328,368 $18.4 Million
Q1 2021 May 17, 2021	BUY	$17.65 - $24.16 $593,746 - $812,742	33,640 Added 19.67%	204,667 $4.28 Million
Q4 2020 Feb 16, 2021	SELL	$12.83 - $17.84 $75,581 - $105,095	-5,891 Reduced 3.33%	171,027 $2.84 Million
Q3 2020 Nov 10, 2020	BUY	$11.01 - $18.52 $88,542 - $148,937	8,042 Added 4.76%	176,918 $3.01 Million
Q2 2020 Aug 14, 2020	BUY	$11.11 - $24.72 $258,507 - $575,184	23,268 Added 15.98%	168,876 $2.8 Million
Q1 2020 May 11, 2020	BUY	$10.74 - $16.32 $1.56 Million - $2.38 Million	145,608 New	145,608 $1.69 Million

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.